Aetna considers home spirometry medically necessary for lung transplant recipients.
Aetna considers home spirometry experimental and investigational for all other indications (asthma and persons with other chronic pulmonary diseases/disorders (e.g., emphysema)) because there is inadequate evidence that it will improve the care of persons with these disorders.
Notes: Home spirometry for monitoring lung function should not be confused with incentive spirometry. Use of an incentive spirometer may be medically necessary for preventing post-operative atelectasis.
Home spirometry should also not be confused with peak flow meters.
Home monitoring of pulmonary function by means of home spirometry (also known as ambulatory spirometry) has been primarily investigated among lung transplant recipients as a way to provide early diagnosis of infection and rejection. More recently, home spirometry has also been studied as a means of monitoring lung function in asthmatics.
Home spirometry monitoring should not be confused with incentive spirometry; the latter is a simple device that is used following thoracic surgery to mobilize secretions and increase lung volumes to reduce postoperative complications.
Home spirometry usually employs battery-operated spirometers, which allows daily measurement of respiratory function including forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). Sometimes, a bronchodilator or a beta-2 agonist is given, and the spirometry is repeated. In general, home spirometry does not refer to the use of peak flow meters, which measure peak expiratory flow (PEF), an indicator of both the existence and the severity of airflow obstruction.
There is inadequate evidence that home spirometry will improve the patient care of asthmatics, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders. Wensley and Silverman (2001) concluded that even under ideal conditions, home spirometry provides an incomplete (and therefore potentially biased) picture of long-term changes in pulmonary function.
Tovar and Gums (2004) stated that despite recent advances in medical technology, monitoring of asthma and COPD has not changed significantly. Pulmonary function tests continue to be the gold standard for evaluating airway obstruction and/or restriction. Clinical trials that will evaluate outcomes such as decreased number of hospitalizations, emergency department visits, unscheduled visits to physicians, and days absent from school or work are needed to determine the utility of new monitoring technologies such as portable spirometers that can be used at home without the need for supervision.
Brouwer and colleagues (2006) examined the relationship of PEF and FEV1 variation to other estimates of asthma severity in children, using an electronic home spirometer with automatic data storage. Over a 3-month period, 36 children with mild-to-moderate persistent asthma recorded PEF and FEV1 electronically twice daily and noted an asthma severity score in a written diary. Bronchial responsiveness was evaluated at the beginning and bronchodilator response and asthma-specific quality of life at the end of the study. Variations in PEF correlated significantly but weakly to bronchial responsiveness and bronchodilator response, but not to the asthma severity score or quality-of-life scores. Within-individual correlations between asthma severity scores and home spirometry indices and between PEF and FEV1 were highly variable. The authors concluded that variations in PEF and FEV1, obtained by home spirometry, show poor concordance with other indices of disease activity and with each other. This limits the usefulness of home spirometry in childhood asthma.
Brouwer et al (2007) assessed the agreement in vivo between measurements of lung function on an electronic spirometer and those obtained by the gold standard, a hospital lung function laboratory pneumotachograph. A total of 50 stable asthmatic children (33 boys), aged 6 to17 years, performed PEF and FEV1 measurements according to international guidelines on a portable home spirometer and on the hospital pneumotachograph in random order. All measurements complied to standard quality criteria. The PEF and FEV1 values recorded with the home spirometer and on the hospital pneumotachograph were compared. All children performed reproducible high-quality measurements on both spirometers. Values for PEF on the home spirometer were considerably lower than on the laboratory pneumotachograph (95 % confidence interval [CI] for difference in PEF: 14 to 30 L/min; p < 0.0001). Individual differences in PEF between the 2 devices could be greater than 100 L/min. The FEV1 values were slightly, but significantly, lower on the home spirometer (95 % CI for difference in FEV1: 0.02 to 0.1 L; p = 0.0018). The authors concluded that a home spirometer provides reproducible and quality acceptable measures in children with asthma when performed under professional supervision and encouragement. Mean PEF and FEV1 values recorded on this home spirometer are significantly lower than those on a hospital pneumotachograph, and individual differences may be large. Thus, home spirometry may not be interchanged with pneumotachography in a lung function laboratory.
Brouwer et al (2010) evaluated the usefulness of home spirometry in children with non-specific lower respiratory tract symptoms, to diagnose or exclude asthma. Subjects were school-aged children, referred by their general practitioner because of chronic respiratory symptoms of unknown origin, the diagnosis of asthma was made or excluded by a pediatric pulmonologist (gold standard), based on international guidelines and a standardized protocol. Additionally, children measured PEF and FEV1 twice-daily for 2 weeks on a home spirometer, from which diurnal variation was calculated. These results (index test) were not revealed to the pediatric pulmonologist. The value of home spirometry to diagnose asthma was calculated. A total of 61 children (27 boys) were included in this study (mean age of 10.4 years; range of 6 to 16 years). Between asthma and no asthma, the mean difference in PEF variation was 4.4 % (95 % CI: 0.9 to 7.9; p = 0.016) and in FEV1 variation 4.5 % (95 % CI: 1.6 to 7.4; p = 0.003). Sensitivity and specificity, based on the 95th-percentile of the reference values for PEF and FEV1 variation (12.3 % and 11.8 %, respectively) were 50 % and 72 % for PEF variation and 45 % and 92 % for FEV1 variation. The likelihood ratio was 1.8 for PEF and 5.6 for FEV1. The authors concluded that the contribution of home spirometry in the diagnosis of asthma in children with non-specific respiratory symptoms is limited.
Deschildre et al (2012) concluded that a treatment strategy based on daily FEV(1) monitoring via spirometry with medical feedback did not reduce severe asthma exacerbations. The investigators sought to assess the outcome (severe exacerbations and healthcare use, lung function, quality of life and maintenance treatment) of a strategy based on daily home spirometry with teletransmission to an expert medical center and whether it differs from that of a conventional strategy. A total fo 50 children with severe uncontrolled asthma were enrolled in a 12-month prospective study and were randomized into 2 groups: (i) treatment managed with daily home spirometry and medical feedback (HM), and (ii) conventional treatment (CT). The children's mean age was 10.9 years (95 % CI:10.2 to 11.6 years); 44 children completed the study (21 in the HM group and 23 in the CT group). The median number of severe exacerbations per patient was 2.0 (interquartile range 1.0 to 4.0) in the HM group and 3.0 (1.0 to 4.0) in the CT group (p = 0.38 with adjustment for age). The investigators reported that there were no significant differences between the 2 groups or unscheduled visits (HM 5.0 (3.0 to 7.0), CT 3.0 (2.0 to 7.0); p = 0.30), lung function pre-β(2)-agonist FEV1 (p= 0.13), Pediatric sthma Quality of Life Questionnaire scores (p = 0.61) and median daily dose of inhaled corticosteroids (p = 0.86).
Osthoff and Leuppi (2010) reviewed the literature regarding the management of patients with COPD after hospitalization for an acute exacerbation. Guidelines recommend a follow-up 4 to 6 weeks after hospitalization to assess coping strategies, inhaler technique, the need for long-term oxygen therapy and the measurement of FEV1. This review discussed the follow-up of patients with exacerbations of COPD, the use and value of spirometry in their further management, the potential benefit of home monitoring, the value of long-term oxygen therapy, the value of self-management programs including the use of action plans, the potential benefit of non-invasive ventilation as well as the value of early rehabilitation. There is insufficient literature to allow specific recommendations and to define components of a care plan following hospitalization for an acute exacerbation; however, early rehabilitation should be included.
A randomized study found no statistically significant differences in number of emergency room visits or hospital admissions in persons with COPD who were managed with home spirometry (Jodar-Sanchez et al, 2013). The study found a non-significant trend in improved quality of life in subjects managed with home spirometry. The investigators conducted a pilot study of the effectiveness of home telehealth for patients with advanced COPD treated with long-term oxygen therapy. Patients were randomized into a telehealth group (n = 24) and a control group (n = 21) who received usual care. Patients in the telehealth group measured their vital signs on weekdays and performed spirometry on 2 days per week. The data were transmitted automatically to a clinical call center. After 4 months of monitoring the mean number of accident and emergency department visits in the telehealth group was slightly lower than in the control group (0.29 versus 0.43, p = 0.25). The mean number of hospital admissions was 0.38 in the telehealth group and 0.14 in the control group (p = 0.47). During the study a total of 40 alerts were detected. The clinical triage process detected 8 clinical exacerbations which were escalated by the case manager for a specialist consultation. There were clinically important differences in health-related quality of life in both groups. The mean score on the SGRQ was 10.9 versus 4.5 in the control group (p = 0.53). The EuroQol-5D score improved by 0.036 in the telehealth group and by 0.003 in the control group (p = 0.68).
Kugler and colleagues (2009) stated that effects of non-adherence to home spirometry (HS) on detection of the bronchiolitis obliterans syndrome (BOS) and on graft survival are unknown. In a 7-year prospective, cohort study, these researchers assessed non-adherence longitudinally using electronic spirometry for 24 months. During follow-up, BOS, re-transplantation, and survival were stratified by adherence groups. Electronic monitoring of 226 patients confirmed that 123,487 measures were performed. Period prevalence was 0.76 measures per patient day and decreased significantly over time (p < 0.0001). During follow-up, BOS developed in 32 % of patients; 5 % received a second transplant, and mortality rate was 19 %. Kaplan-Meier event-free analysis showed decreased freedom from BOS time in non-adherers (30 %) compared with good (43 %) or moderate adherers (19 %) (log rank 6.008; p < 0.014) and a tendency toward lower re-transplantation rates (log rank 3.14; p < 0.07). Mantel Cox regression revealed no impact of adherence on patient survival. The authors concluded that this was the first study assessing non-adherence to HS based on electronic monitoring in relation to long-term outcome following lung transplantation. Non-adherers showed decreased freedom from BOS in the largest sample to date, but did not impact survival.
Wang et al (2013) conducted a study to develop, implement, and test an automated decision system to provide early detection of clinically important broncho-pulmonary events in a population of lung transplant recipients following a home spirometry monitoring protocol. Spirometry and other clinical data were collected daily at home by lung transplant recipients and transmitted weekly to the study data center. Decision rules were developed using wavelet analysis of declines in spirometry and increases in respiratory symptoms from a learning set of patient home data and validated with an independent patient set. The investigators reported that, using FEV1or symptoms, the detection captured the majority of events (sensitivity, 80 to 90 %) at an acceptable level of false alarms. On average, detections occurred 6.6 to 10.8 days earlier than the known event records. The investigators concluded that this approach is useful for early discovery of pulmonary events and has the potential to decrease the time required for humans to review large amount of home monitoring data to discover relatively infrequent but clinically important events.
Finkelstein et al (2013) conducted a randomized controlled trial (RCT) to determine the relative performance of a computer-based Bayesian algorithm compared with a manual nurse decision process for triaging clinical intervention in lung transplant recipients participating in a home monitoring program. This RCT had 65 lung transplant recipients assigned to either the Bayesian or nurse triage study arm. Subjects monitored and transmitted spirometry and respiratory symptoms daily to the data center using an electronic spirometer/diary device. Subjects completed the Short Form-36 (SF-36) survey at baseline and after 1 year. End-points were change from baseline after 1 year in FEV1 and quality of life (SF-36 scales) within and between each study arm. The authors found that there were no statistically significant differences between groups in FEV1 or SF-36 scales at baseline or after 1 year. Results were comparable between nurse and Bayesian system for detecting changes in spirometry and symptoms, providing support for using computer-based triage support systems as remote monitoring triage programs become more widely available. The authors concluded that the feasibility of monitoring critical patient data with a computer-based decision system is especially important given the likely economic constraints on the growth in the nurse workforce capable of providing these early detection triage services.
de Wall et al (2014) evaluated the utility of home spirometry (HS) versus office spirometry (OS) in assessing treatment response to azithromycin in BOS. In this study, 239 lung transplant recipients were retrospectively studied. Change in TEV1 (ΔFEV1 ± 10 %) from FEV1 at azithromycin initiation for greater than or equal to 7 consecutive days in HS or greater than or equal to 2 measures in OS were taken as cut-off for response or progression. Based upon HS, 161/239 (67 %) patients were progressive despite macrolide, 19 of who exhibited transient improvement in FEV1 (11 %). Time to progression was 29 (13 to 96) days earlier with HS than in OS. A total of 46 (19 %) recipients responded in HS after median 81 (22 to 343) days, while 22 % remained stable. Concordance in azithromycin treatment response between OS and HS was observed in 210 of 239 patients (88 %). Response or stabilization conferred significant improvement in survival (p = 0.005). Transient azithromycin responders demonstrated improved survival when compared to azithromycin refractory patients (p = 0.034). The investigators concluded that HS identified azithromycin refractory patients significantly earlier than OS, possibly facilitating aggressive treatment escalation that may improve long-term outcome. The investigators recommended that treatment response to azithromycin be assessed 4 weeks after initiation. Responders demonstrated best survival, with even transient response conferring benefit. Macrolide-refractory BOS carried the worst prognosis.
An UpToDate review on “Evaluation and treatment of acute lung transplant rejection” (Pilewski, 2015) states that “Spirometry -- Many centers, including ours, utilize patient-administered, home spirometry several times a week to monitor lung function. All centers perform spirometry at the time of follow-up visits. Once postoperative function has stabilized, the variation in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) is less than 5 %. Spirometry has been reported to have a sensitivity of 60 % in detecting rejection (grade greater than or equal to A2) or infection among bilateral lung transplant recipients. A decline of 10 % in spirometric values that persists for more than 2 days has been reported to indicate either rejection or infection. In single lung transplant recipients, spirometry is less helpful as changes may reflect progression of the underlying disease in the native lung”.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|CPT codes covered if selection criteria are met:|
|94014||Patient-initiated spirometric recording per 30-day period of time; includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and physician review and interpretation|
|94015||recording (includes hook-up, reinforced education, data transmission, data capture, trend analysis, and periodic recalibration)|
|94016||physician review and interpretation only|
|HCPCS codes covered if selection criteria are met:|
|E0487||Spirometer, electronic, includes all accessories|
|Other HCPCS codes related to the CPB:|
|A9284||Spirometer, nonelectric, includes all accessories|
|S8096||Portable peak flow meter|
|ICD-10 codes covered if selection criteria are met:|
|T86.810 - T86.819||Complications of lung transplant [for monitoring of lung function at home]|
|Z94.2||Lung transplant status [for monitoring of lung function at home]|
|ICD-10 codes not covered (not all inclusive):|
|J09.X1 - J18.9||Influenza and pneumonia [for monitoring of lung function at home]|
|J40 - J94.9||Chronic lower respiratory diseases, lung diseases due to external agents, other respiratory diseases principally affecting the interstitium, suppurative and necrotic conditions of the lower respiratory tract, other diseases of the pleura [for monitoring of lung function at home]|
|J95.4||Chemical pneumonitis due to anesthesia [for monitoring of lung function at home]|
|J95.5||Postprocedural subglottic stenosis [for monitoring of lung function at home]|
|J95.851 - J95.89||Complications of respirator (ventilator) [for monitoring of lung function at home]|
|J98.9||Respiratory disorder, unspecified [for monitoring of lung function at home]|
|R09.1||Pleurisy [for monitoring of lung function at home]|
|Z87.01 - Z87.09||Personal history of diseases of the respiratory system [for monitoring of lung function at home]|